AMLX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Amylyx Pharmaceuticals Inc (AMLX) is not a strong buy right now for a beginner investor with a long-term strategy. The stock has weak financial performance, insider selling trends, and no recent positive news catalysts. While analysts are optimistic about the company's drug pipeline, the current technical indicators and financials do not support an immediate entry point. Holding off for now is recommended.
The MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 35.832, and moving averages are converging, showing no clear trend. The stock is trading near its support level of 13.339, with resistance at 14.718. Overall, the technical indicators suggest a weak trend.
Analysts have raised price targets and maintain high confidence in the Phase 3 LUCIDITY trial for avexitide, which could address a significant unmet medical need. The stock has a 70% chance to increase by 5.6% in the next month.
Insiders are selling heavily, with a 2291.45% increase in selling activity over the last month. Financial performance is weak, with declining net income, EPS, and gross margin. No recent news or significant hedge fund activity.
In Q4 2025, revenue remained at 0 with no growth. Net income dropped by -12.11% YoY to -$32,999,000. EPS declined by -45.45% YoY to -0.3, and gross margin dropped to 0, indicating poor financial health.
Analysts are optimistic, with multiple Buy ratings and price targets raised to as high as $34. Confidence in the LUCIDITY trial is high, with a 65%-75% probability of success for avexitide.
